HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Spero Therapeutics (NASDAQ:SPRO) and maintained a $6 price target.
August 01, 2023 | 10:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Spero Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $6.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Spero Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100